US Edition
Gene Therapy Cuts Bleeding and Medicine for Hemophilia B Patients for Over a Decade
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Study: Benefits of hemophilia B gene therapy last more than a decade
The benefits of a one-time gene therapy were sustained for up to 13 years among men with severe hemophilia B with no new safety concerns emerging, according to newly published results from a clinical trial. The findings, which encompass the longest ever follow-up for a gene therapy study in hemophilia B, support the long-term benefits of gene therapy for this patient group. “It’s incredibly rewarding to see the sustained safety and efficacy, whi…
The president of the Xunta, Alfonso Rueda, has announced that his government has agreed to authorize the investment of 15.6 million euros in the purchase of the first gene therapy drugs for the treatment of haemophilia B. According to the president, the tender of the successive supply of the medication, destined to the approach of hereditary blood clotting disorder with gene therapy, demonstrates "the validity of public health" and makes Galicia…
Green light to 15.6 million for the purchase of the first medicines, with the expectation that eight patients can benefit ...
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
